In this episode of the Psychedelic Spotlight Podcast, we put a spotlight on the unique and unsuspecting intersection where psychedelics and real estate are beginning to converge as the psychedelic industry moves closer to mass adoption.
HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).
This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.
In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.
Timestamps:
0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #CMPS #PsychedelicTherapy
UK venture capital fund The Conscious Fund is working to make psychedelics more accessible and functional in various capacities.
What variables, if any, can predict the intensity of…
More people are turning to microdosing and functional mushrooms to improve mood and health, and the Microdosing Collective is here to help
Researchers find that there were significantly lower levels of complex trauma symptoms and feelings of internalized shame in study participants that had used psychedelics therapeutically.
This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
